Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other Operating Expenses: 2009-2024

Historic Other Operating Expenses for Lineage Cell Therapeutics (LCTX) over the last 7 years, with Dec 2024 value amounting to $334,000.

  • Lineage Cell Therapeutics' Other Operating Expenses fell 86.84% to $5,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $15.1 million, marking a year-over-year increase of 4219.20%. This contributed to the annual value of $334,000 for FY2024, which is 50.22% down from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Other Operating Expenses stood at $334,000 for FY2024, which was down 50.22% from $671,000 recorded in FY2023.
  • Lineage Cell Therapeutics' Other Operating Expenses' 5-year high stood at $671,000 during FY2023, with a 5-year trough of $334,000 in FY2024.
  • For the 2-year period, Lineage Cell Therapeutics' Other Operating Expenses averaged around $502,500, with its median value being $502,500 (2023).
  • Data for Lineage Cell Therapeutics' Other Operating Expenses shows a maximum YoY plummeted of 50.22% (in 2024) over the last 5 years.
  • Over the past 2 years, Lineage Cell Therapeutics' Other Operating Expenses (Yearly) stood at $671,000 in 2023, then tumbled by 50.22% to $334,000 in 2024.